Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Krill oil boom is real

There’s a new type of oil that’s causing a major stir in the markets. This oil boom has nothing to do with crude oil or energy though. But it still has the potential to be just as profitable. I’m talking about krill oil. ...
Andrew Mickey | October 28, 2012 |

From COVID to Nicotine Treatments, this Bio Stock is One to Watch

(Image via Lexaria Bioscience Corp.) There’s no shortage of excitement over potential COVID-19 vaccines. Just looking at the response to news around these developments is evidence of that, and one Company is working on a transformative, patented tech...
Stockhouse Editorial | December 1, 2020 |

Biopharma Buys 'Insurance Policy Ahead of First Commercial Launch'

The terms of the financial transaction and the potential reasons for it are discussed in a BTIG report. In a June 26 research note, BTIG analyst Thomas Shrader reported that Esperion Therapeutics Inc. (ESPR:NASDAQ) agreed to an "up to $200 capped, tier...
Streetwise Reports | July 3, 2019 |

Cypress: 5 first steps to a lithium mine

Building a mine is a succession of confidence-building steps. In the initial phases of exploration, when land is staked, samples are taken (channel, rock, chip) and surveys (geochemical and geophysical) are conducted, junior resource investors have a low level of confidence ...
Richard (Rick) Mills | May 2, 2019 |

Kardashian-Style News Bomb: Already Big Ashram Gets Bigger And Bigger

Bigger is Better (at least in this respect) What a pleasant surprise! The Ashram Rare Earth and Fluorspar Deposit continues to grow. As announced today by Commerce Resources Corp. , recent core assays for vertical drilling at Ashram has disc...
Stephan Bogner | November 28, 2019 |

Amarin Shares Up Sharply on Increased Revenues and Vascepa's Progress

Amarin shares are spiking up today by more than 12% on greater than five times 50-day average volume after the company updated its annual revenue forecast and plans for Vascepa. Amarin Corp. (AMRN:NASDAQ) ADR shares are up sharply today after the com...
Streetwise Reports | July 3, 2019 |

Exicure's Collaboration with Allergan on Treating Hair Loss Disorders Sends Shares Higher

Shares of Exicure Inc. opened 30% higher today after the firm reported that it entered into a collaboration agreement with Allergan to discover and develop SNA-based treatments for hair loss disorders. The terms of the deal provide for a $25 million upfront payment to Exicure ...
Streetwise Reports | November 15, 2019 |

What Is Vanadium and Why Should I Care?

Summary Vanadium is the 20th most abundant element in the earth’s crust and the 13th most available metal, but it is a challenge to recover. Heap leaching is a method that has taken low grade deposits (gold, copper, nickel and cobalt) and recovers sufficient ...
Michael Drozd | March 29, 2019 |

Topline Results from Lipid-Lowering Trial 'Just What the Doctor Ordered'

The study data and their implications are provided in a BTIG report. In an Aug. 29 research note, BTIG analyst Thomas Shrader reported that just released topline data are "as hoped" from Esperion Therapeutics Inc.'s (ESPR:NASDAQ) Phase 2 trial of bempedoic acid-ezet...
Streetwise Reports | September 5, 2019 |

Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer...

Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer for Investigative Antisense Therapy, Shares Up 30% Akcea Therapeutics' shares are trading 30% higher today on news that it has entered into a worldwide exclusive licensing agreement with Pfizer for AKCEA-ANG...
Streetwise Reports | October 8, 2019 |
1 2 3 4 5 6 7 8